Evolus (EOLS) Capital Expenditures Growth (5y) (2023 - 2026)
Evolus (EOLS) Capital Expenditures Growth (5y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.84 Bn | 32.10 Bn | 1.97 Bn |
| 3 | Zoetis | 32.67 Bn | 30.73 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.69 Bn | 23.63 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.12 Bn | 20.97 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - |
| 7 | Viatris | 20.24 Bn | 18.44 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.83 Bn | 16.51 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.22 Bn | 785.00 Mn |
| 10 | Evolus | 401.55 Mn | 351.76 Mn | 48.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.38% |
| Dec 31, 2025 | 59.99% |
| Sep 30, 2025 | 23.48% |
| Jun 30, 2025 | 16.69% |
| Mar 31, 2025 | 13.68% |
| Dec 31, 2024 | 237.82% |
| Jun 30, 2024 | 25.43% |
| Dec 31, 2023 | 76.00% |
| Sep 30, 2023 | 125.78% |
| Jun 30, 2023 | 96.70% |